NorVision Therapeutics Inc.

• Pioneering - breakthrough science.
• NorVision’s candidate drugs are designed to serve unmet needs in the Age Related Macular Degeneration (AMD) market.
• AMD represents one of the largest emerging pharmaceutical markets.
• NorVision is about 1.0 - 1.5 years from entering clinical trials with its first candidate drug.
• Technologies developed by NorVision are scientifically proven over years of rigorous laboratory testing.
• NorVision has a highly attractive pipeline of candidate products with sustainable competitive advantages.
• The eye diseases targeted by NorVision have clinical trial endpoints which are distinct, clear and quickly verifiable.
• A strong and dynamic team with years of industry experience.
• Clear – high growth business model.
• Meeting important social need by alleviating human suffering on a global scale.

NorVision is a biopharmaceutical company with two candidate drugs, in sequential PreClinical Development, for unmet needs in the Age Related Macular Degeneration (AMD) market. Other candidate drugs within NorVision’s technological scope, will also be advanced in a sequential manner. Once NorVision’s CAD$ 3M financing round is completed, we will be about 1.0 - 1.5 years away from entering clinical trials with the most advanced candidate drug in its pipeline – an orally active therapeutic for wet-AMD. NorVision will form strategic alliances with large pharmaceutical companies, and market it’s therapeutics worldwide.

In developed countries, an estimated third of those 55-74 years of age, and 40% of those over 74 years of age have AMD. This is the leading cause of blindness for people over 55 years of age. In Canada and the US, the combined annual cost of AMD to the national economies is estimated to be US$ 33 billion¹. AMD will have increasing social impact, due to aging Baby Boomers, and greater life expectancy. The current market for AMD is estimated to be in the tens of billions of dollars.

¹Brown et al, Trans Am Ophthalmol Soc. 103:173-186, 2005. Brown et al, CJO 40(3): 277-287, 2005.

Haroutioun M. Hasséssian, B.Sc., M.Sc., Ph.D. (co-founder). President and CEO (2000- ). Active within the biopharmaceutical industry for more than a decade, Dr Hasséssian has biopharmaceutical experience in different areas of the industry, and has received extensive formal scientific as well as business training from leading institutions and companies. Dr Hasséssian has over 15 years of proven managerial skills with teams of knowledge workers. He has advised internationally public biopharmaceutical companies, and private finance companies, as well as governments on biopharmaceutical related policy and projects. Dr. Hasséssian has been the initiator of several projects, bringing together major corporations with similar interests, as well as introducing multinational corporations to government. He has served on the governing bodies of a large number of organizations. He is recipient of numerous distinctions and awards.

Haroutioun M. Hasséssian, PhD
President and CEO - NorVision Therapeutics Inc.
3465 Redpath, suite 303
Montréal, Québec, CANADA, H3G 2G8
tel:     1-514-594-3477          
email:     norvision.therapeutics@videotron.ca